Systematic review of the prevalence of Long Covid

Mirembe Woodrow, Charles Carey, Nida Ziauddeen, Rebecca Thomas, Athena Akrami, Vittoria Lutje, Darren C Greenwood\*, Nisreen A Alwan\*  
\*Equal contribution as senior authors

* Mirembe Woodrow MSc, School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK
* Charles Carey MBChB, Manchester University NHS Foundation Trust and The University of Manchester, Manchester, UK
* Nida Ziauddeen PhD, School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK and NIHR Applied Research Collaboration Wessex, Southampton, UK
* Rebecca Thomas MBChB, MPH, University of Liverpool, Liverpool, UK
* Athena Akrami PhD, Sainsbury Wellcome Centre, University College London, London, UK and Patient-led Research Collaborative, Washington DC, USA
* Vittoria Lutje PhD, Cochrane Infectious Diseases Group, Liverpool, UK
* Darren C Greenwood PhD, School of Medicine, University of Leeds, UK
* Nisreen A Alwan PhD, School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK, NIHR Applied Research Collaboration Wessex, Southampton, UK and NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK

Correspondence to: Prof Nisreen A Alwan, School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK

ORCID iD: 0000-0002-4134-8463

Email: [n.a.alwan@soton.ac.uk](mailto:n.a.alwan@soton.ac.uk)

Alternate corresponding author: Mirembe Woodrow, School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK, [m.woodrow@soton.ac.uk](mailto:m.woodrow@soton.ac.uk)

**Key points**: In a systematic review of 130 publications, prevalence estimates of Long Covid (>12 weeks) after SARSCoV2 infection differed according to how persistent symptoms/pathology were identified and measured, and ranged between 0% - 93% (pooled estimate 42.1%, 95% prediction interval: 6.8% to 87.9%).

**Key words**: Long Covid, Systematic Review, Prevalence, SARSCoV2

# Summary (250words)

## Background:

Long Covid occurs in those infected with SARSCoV2 whose symptoms persist or develop beyond the acute phase. We conducted a systematic review to determine the prevalence of persistent symptoms, functional disability or pathological changes in adults or children at least 12 weeks post-infection.

Methods: We searched key registers and databases from 1st January 2020 to 2nd November 2021, limited to publications in English and studies with at least 100 participants. Studies where all participants were critically ill were excluded. Long Covid was extracted as prevalence of at least one symptom or pathology, or prevalence of the most common symptom or pathology, at 12 weeks or later. Heterogeneity was quantified in absolute terms and as a proportion of total variation and explored across pre-defined subgroups (PROSPERO ID CRD42020218351).

Results: 120 studies in 130 publications were included. Length of follow-up varied between 12 weeks - 12 months. Few studies had low risk of bias. All complete and subgroup analyses except one had I2 ≥ 90%, with prevalence of persistent symptoms range of 0% - 93% (pooled estimate (PE) 42.1%, 95% prediction interval (PI): 6.8% to 87.9%). Studies using routine healthcare records tended to report lower prevalence (PE 13.6%, PI: 1.2% to 68%) of persistent symptoms/pathology than self-report (PE 43.9%, PI: 8.2% to 87.2%). However, studies systematically investigating pathology in all participants at follow up tended to report the highest estimates of all three (PE 51.7%, PI: 12.3% to 89.1%). Studies of hospitalised cases had generally higher estimates than community-based studies.

Conclusions: The way in which Long Covid is defined and measured affects prevalence estimation. Given the widespread nature of SARSCoV2 infection globally, the burden of chronic illness is likely to be substantial even using the most conservative estimates.

Funding: this systematic review received no specific funding.

# Lay summary

Long Covid is the state of not fully recovering for many weeks, months or years after infection with SARSCoV2, the coronavirus that causes COVID-19 disease. It influences the daily lives of many people globally. We conducted a systematic review of 120 published studies to estimate how common (prevalent) Long Covid is. The studies showed a very wide range of estimates of Long Covid prevalence, with between 0% and 93% of infected people still having signs or symptoms after 12 weeks. However, we could see that studies fell into groups according to how Long Covid was defined and measured. Studies analysing routine healthcare records tended to report lower prevalence, whereas studies investigating damage to organs and tissues reported higher prevalence. We concluded that the way in which Long Covid is defined and measured affects prevalence estimation, which is important for designing future research in this area. Given the high rates of SARSCoV2 infection globally, the burden of Long Covid is likely to be substantial even using the most conservative estimates.

# Introduction

Long Covid is the state of not fully recovering for many weeks, months or years after contracting SARSCoV2 infection. The World Health Organization (WHO) defines Post COVID-19 Condition (Long Covid) as the condition occurring in individuals with a history of probable or confirmed SARSCoV2 infection 3 months after the onset with symptoms that last at least 2 months, cannot be explained by an alternative diagnosis and generally impacts everyday functioning(1). These symptoms may be the same as the acute illness or new symptoms developing weeks or months after the acute phase. Clinical guidelines(2, 3) in the UK and the US consider Long Covid as symptoms ongoing for four weeks or more.

Long Covid can occur across the spectrum of severity of initial infection(4). A wide range of symptoms have been reported with exhaustion, breathlessness, muscle aches, cognitive dysfunction, headache, palpitations, dizziness and chest tightness or heaviness amongst the most common(5, 6). Patients are still struggling to access adequate recognition, support, medical assessment and treatment(7, 8).

Studies assessing the prevalence of Long Covid have produced wide-ranging results due to varying settings, case definitions, population denominators and methods of ascertainment. This is exemplified in the UK Office for National Statistics estimates of Long Covid during 2020-21 where three different approaches were used resulting in three different estimates: approach 1 estimated 5.0% prevalence based on respondents reporting any of 12 common symptoms at 12-16 weeks after infection; approach 2 estimated 3.0% prevalence based on respondents reporting any of 12 common continuous symptoms at least 12 weeks after infection; and approach 3 estimated 11.7% prevalence based on respondents describing themselves as having Long Covid(9).

For the purposes of this review, we define Long Covid as persistent (constant, fluctuating or relapsing) symptoms and/or functional disability and/or the development of new pathology following SARSCoV2 infection for equal or more than 12 weeks from onset of symptoms or from time of diagnosis, in people where the infection is self-described, clinically diagnosed, and/or diagnosed through a laboratory test.

We aimed to systematically collate, appraise and synthesise studies that describe the prevalence of Long Covid and to characterise its typology including patient demographics, symptoms/function disability and pathology.

# Methods

## Search strategy and selection criteria

Included study designs were cohort, cross-sectional and case control studies with an estimate of the denominator where participants were followed-up/assessed at a minimum of 12 weeks post-infection. Studies were restricted to those published in English between 1st January 2020 and 2nd November 2021, including peer-reviewed articles, online reports, letters, and preprints. Only studies with a sample size of 100 or more participants (at the time of follow-up assessment if longitudinal study) were included (50 or more per subgroup).

Studies of adults and children with a confirmed or probable SARSCoV2 infection in any age group (as defined by each study) were included. The control group in studies that included one is individuals with a confirmed or probable case of SARSCoV2 infection (as defined by the study) who have recovered (duration as defined by study as long as under 12 weeks from symptom onset or confirmation of infection) and have no new pathology attributed to SARSCoV2 infection. Studies that compared population-based prevalence as the control arm were excluded from the control analysis.

Community-based, hospital-based, and mixed studies were all included, apart from studies that only reported outcomes for critically ill patients admitted to intensive care, because this review did not aim to estimate delayed recovery following ICU admission (post-ICU syndrome). Patients who were not hospitalised within two weeks of symptom onset but were subsequently hospitalised were counted as non-hospitalised for the purpose of this review.

A systematic search was conducted using MEDLINE (Ovid), Embase (Ovid), the Cochrane Covid-19 Study register (www.covid-19.cochrane.org; includes Cochrane Central Register of Controlled Trials (CENTRAL), WHO International Clinical Trials Registry Platform (ICTRP), medRxiv, Cochrane CENTRAL, MEDLINE (PubMed), ClinicalTrials.gov, and the WHO Global research on coronavirus disease (COVID-19) database(10). The initial search was run on 13 November 2020 and updated on 2 November 2021, both by VL. An example of the search strategy applied to Medline is provided in the Supplementary material; it was adapted for other databases as needed.

The screening management software Covidence was used to screen for eligibility. All articles were screened independently by two reviewers at each stage (title, abstract, and full text) with any discrepancies resolved by NAA. This review is reported in line with PRISMA guidelines(11). The protocol was published on the international prospective register of international reviews, PROSPERO (CRD42020218351): https://www.crd.york.ac.uk/prospero/display\_record.php?RecordID=218351.

## Data analysis

Data for each study was extracted independently by two of four reviewers (MW, DCG, CC, NZ). Any discrepancies were resolved by consensus between the two reviewers for each study or by a third reviewer (NAA). Where multiple publications were identified as originating from the same study, all data was extracted but each data point was only used once in the analysis. In addition to excluding duplicate reports, or duplicate results from the same study, a number of general decisions were made to cope with multiple publications from the same study, either focusing on different lengths of follow-up, different timepoints, or different subgroups. These were guided by principles of (1) avoiding double counting individuals, (2) using the most appropriate outcome, for example, general Long Covid definition, in the broadest group such as the widest population, largest sample, most recent update, (3) unless stratifying by length of follow-up, we took the earliest and/or most complete follow-up as the main result.

The primary outcome is Long Covid, defined as non-recovery from COVID-19, according to symptoms, functional ability or pathology. SARSCoV2 infection can be confirmed, probable or suspected with prolonged symptoms (including but not limited to those explicitly defined as ‘new onset’), functional disability or pathology for equal to or more than 12 weeks from onset of symptoms or positive test date (as defined by the study). Secondary outcomes included the demographics of people with Long Covid in relation to each study’s denominator, prevalence of specific persistent or relapsing symptoms, prevalence of functional disability, and the characterisation of post-COVID-19 pathology.

A Long Covid-specific risk of bias tool was developed, based on the Newcastle-Ottawa scale, but tailored to the relevant sources of bias. The domains used are reported in Supplementary Table 3. Risk of bias was particularly assessed in relation to the denominator, how the symptoms were assessed (active or passive elicitation of the symptoms) and hospital stay. Subgroup analysis by risk of bias was performed. In studies where follow-up was measured post-hospital admission or discharge, symptom onset was estimated to have been 7 or 14 days prior to discharge respectively and estimated as 21 days if follow-up was measured from a post-infection negative test.

The prevalence was extracted as cumulative incidence. In extracting the prevalence of persistent symptoms, we used either prevalence of at least one symptom or pathology, or the prevalence of the most common symptom/pathology, depending on the data reported by the study. Data for each symptom was extracted separately in studies that reported on the prevalence of individual symptoms but did not provide an overall estimate of prevalence of Long Covid. We used the symptom with the highest estimate as our best estimate of overall prevalence, though it is likely to be an underestimate of actual prevalence. In studies with controls, the prevalence of the same symptom was used for comparison. Where length of follow-up varied between study participants, we report a measure of average (e.g. mean or median) length of follow-up, or the midpoint of the reported range.

All analysis was conducted in Stata version 17(12). The distribution, prevalence estimates, numerators, denominators, and assessment time points in different populations was qualitatively summarised. We used random-effects meta-analysis on the logit of the proportions to ensure estimates and confidence limits did not go below 0% or over 100%, transforming back to the original scale for presentation.

The heterogeneity was quantified both in absolute terms (range of individual study estimates) and as a proportion of total variation (I2), and explored across pre-defined subgroups described below. In a variation to our protocol, we present pooled estimates alongside 95% prediction intervals to evaluate and incorporate uncertainty in the analysis, as recently recommended for prevalence studies, where true between-study heterogeneity is expected(13, 14) . Heterogeneity was explored by stratifying on pre-defined subgroups: outcome type (pathology, symptom, functional status), geographical region (China, Europe, North America, Mixed and other), source of sample (community, healthcare workers, outpatients, hospital inpatients), length of follow-up, study design, confirmed diagnosis, and other risk of bias domains. We also stratified by severity score based on the WHO Clinical Progression Scale [supplemental methods].

Potential small study effects such as publication bias were investigated using contour-enhanced funnel plots and Egger's test of funnel plot asymmetry.

Role of funding source

None

Patient Consent Statement

This systematic review analysed publicly available data included in published scientific papers. No patient consent or ethical approval were required.

# Results

Literature search

The searches found 11,518 studies in total. After deduplication and title and abstract screening, 457 full text studies were assessed for eligibility. Hand-searching sourced an additional 9 studies and in total 130 publications were included, 120 of which were discrete studies (Figure 1). 24 studies were conducted in China (including Hong Kong), 66 in Europe, 14 in North America and 16 in various other countries(9, 15-143). Reasons for exclusion are listed in Supplementary Table 1.

Table 1 summarises the included studies’ key characteristics and primary outcome for the first follow-up. Study design was reported as described by each study or designated based on study description if not explicitly stated. Most studies were in adults and included patients who were hospitalised in the acute phase (24 studies with <10% of the sample hospitalised in the acute phase). However, hospitalisation did not always correspond with disease severity, probably due to local diagnostic, treatment, and containment policies. Most studies used PCR testing to identify COVID-19 cases at baseline. However most did not perform COVID-19 diagnostic tests at follow-up and therefore did not consider the impact of reinfection on their results. Out of the included studies, 21 were community-based studies, 17 outpatient settings, 3 social media and 8 healthcare worker-based studies.

## Prevalence estimates

The prevalence of Long Covid for studies with more than 12 weeks from infection ranged between 0% to 93% (pooled estimate (PE) 42.1%, 95% prediction interval (PI): 6.8% to 87.9%) (Figure 2). For all complete and subgroup analyses except one, I2 was >75%. All subgroup analysis results including pooled estimates and prediction intervals can be found in Supplementary Table 4.

73 included studies had a follow up of 12 weeks to 5 months (PE 39.8% (PI: 5.1% to 89.1%), 49 had a follow-up of 6-11 months (PE 44.9% (PI: 8% to 88.4%), and 12 had a follow-up of 12 months or more (PE 48.5% (PI: 12.7% to 86%). Recognising most are not within-study comparisons, longer follow-up times showed higher pooled estimates (Supplementary Figure 1).

Hospitalisation and severity of acute infection were key factors influencing Long Covid prevalence estimates. The prevalence range in analyses where less than 10% of the participants were hospitalised was 0% to 67% (n=24) (PE 26.4%, PI: 2.6% to 82.8%) but in studies where all participants were hospitalised for acute COVID-19 (n=65), the prevalence range was 5% to 93% (PE 47.5%, PI: 8.3% to 90.0%) (Supplementary Figure 2). 31 analyses had 10% or more of their sample admitted to intensive care unit (ICU) during their acute COVID-19 illness with a Long Covid prevalence estimate of 48.8% (PI: 5.7% to 93.7%) compared to PE 34.9% (PI: 5.2% to 84%) in studies with <5% of their sample admitted to ICU (Supplementary Figure 3). Studies including more hospitalised participants or more patients in ICU tended to report higher prevalence estimates (Supplementary Table 4). Likewise using the WHO CPS, studies including those with ambulatory mild disease (n=38) generally reported lower prevalence estimates (PE 23.5%, PI: 1.6 to 85.7%) than those with hospitalised severe disease who needed oxygen by NIV or high flow (n=27) (PE 54.8%, PI: 7.7 to 94.7%) (Supplementary Figure 4).

The prevalence of not returning to full health/fitness after at least 12 weeks from infection ranged between 8% to 70% (PE 34.5%, PI: 4.3% to 85.9%, n=10) (Supplementary Figure 5). The prevalence of lower quality of life after at least 12 weeks was 31% (n=2) (Supplementary Figure 6). With regard to individual symptoms, common symptoms reported included fatigue (pooled estimate 21.6%, PI: 2.5% to 74.7%, n=72) followed by breathing problems (pooled estimate 14.9%, PI: 1.6% to 64.9%, n=78), sleep problems (pooled estimate 13.2%, PI: 1.2% to 64.9%, n=42), tingling or itching (pooled estimate 11.3%, PI: 0.7% to 69.5%, n=14), and joint/muscle aches and pains (pooled estimate 10.6%, PI: 1.0% to 57.5%, n=61) (Figure 5). With regard to pathology, lung pathology was the most common (pooled estimate 38.9%, PI: 3.4% to 91.9%, n=26) followed by heart (pooled estimate 6.0%, PI: 0.1% to 79.3%, n=12) or neurological pathology (pooled estimate 5.3%, PI: 0.5% to 36.5%, n=11) (Figure 5 and Supplementary Figures 7-40). Pathology tended to be reported in only a small number of studies, with the exception of lung pathology which was reported in 26 studies.

There were very few studies with a low risk of bias (Supplementary Table 2). Few studies used a sample that was representative of all COVID-19 cases in the population. Approximately half of the studies indicated that symptoms had not been present prior to infection, while the rest did not report ascertaining this. When stratifying by risk of bias, generally lower prevalence estimates were seen in studies with COVID-19 diagnoses confirmed for all participants, studies scored as having a representative sample, studies with an internal or external non-COVID-19 comparator, studies that assessed all participants in the same way, and studies based on community participants (Supplementary Figure 41-42).

Comorbidities, ethnicity and other demographic data were not reported in all studies. Higher prevalence of Long Covid was observed in studies where study samples had higher proportions of older people (<50yrs pooled estimate 38.5%, PI: 7.9% to 82.1%; 50+yrs PE 47.7%, PI 7.9% to 90.6%), males (<50% female pooled estimate 45.6%, PI 5.5% to 92.4%; 50%+ female PE 38.7%, PI 8.5% to 81.2%), people of non-white ethnicity (<50% white ethnicity pooled estimate 56.3%, PI 22.3% to 85.2%; 50%+ white ethnicity PE 37.6%, PI 1.7% to 95.3%), diabetes (<10% pre-existing diabetes pooled estimate 35.4%, PI 5.7% to 83.2%; 10%+ pre-existing diabetes PE 51.9%, PI 8.3% to 92.8%), hypertension (<30% pre-existing hypertension pooled estimate 37.3%, PI 7.0% to 82.5%; 30%+ pre-existing hypertension PE 58.5%, PI 16.9% to 90.7%), cardiovascular disease (<10% pre-existing CVD pooled estimate 38.2%, PI 5.9% to 85.9%; 10%+ pre-existing CVD PE 54.7%, PI 9.4% to 93.4%), and other comorbidities including obesity, respiratory disease, liver disease, kidney disease and immunological disorder or allergy (Supplementary Figure 43). Prevalence of Long Covid did not differ substantially with smoking status.

When subgrouping by study design, the range was 0% to 93% (PE 41.3%, PI: 6.0% to 88.6%) in cohort studies and 10% to 82% (PE 45.9%, PI 11.2% to 85.1%) in cross sectional studies. (Supplementary Figure 50). Prevalence estimates derived from assessing Long Covid as self-reported symptoms and function (n=93) on the whole tended to report higher prevalence (PE 43.9%, PI: 8.2% to 87.2%) than those that used clinical coding in healthcare records (n=9) (PE 13.6%, PI 1.2% to 68%). However, studies that had dedicated pathology follow-up of COVID-19 patients (for example pulmonary function tests or scans with pathology discovered at follow-up) tended to report the highest prevalence (n=20) (PE 51.7%, PI 12.3% to 89.1%) (Figure 3). Studies that defined Long Covid as at least one of multiple symptom or pathology domains tended to report a slightly higher prevalence than those that assessed a single symptom/pathology domain (Supplementary Figure 44).

## Comparison to controls

Twenty-four of the 130 publications included comparison to at least one group of controls (Supplementary Figure 45). The majority of studies used test-negative controls (antigen and antibody, with some matching), but others used untested controls. In community-based studies with controls, the relative risk ranged between 1.0 to 51.4 (pooled relative risk 2.7, 95% PI: 0.2 to 39.4) and the absolute risk difference ranged between -1% to 35% (pooled risk difference 10.1%, 95% PI: -12.7% to 32.8%) (Supplementary Figures 46-47). In community-based samples with controls and assessed as having a low risk of bias (n=4), the pooled relative risk of experiencing symptoms/ill health after COVID-19 was 1.33 compared to controls (95% PI: 1.30. 1.36, I2=28.1%) (Figure 4) and the absolute risk difference between cases and controls ranged between 1% to 9% (Supplementary Figure 48).

There was no evidence of small-study effects such as publication bias (Supplementary Figure 49).

# Discussion

This systematic review which included 120 studies assessing Long Covid symptoms, functional status, or pathology published up to November 2021 demonstrates substantial between-study heterogeneity and wide variation in prevalence estimates. This is due to differences sources of study samples (community, outpatient clinic, occupational, hospitalised) and number of assessed symptoms and method of assessment (self-reported individual or collective symptoms, healthcare records, clinical investigations at follow up). The only pooled estimate with low between-study heterogeneity was a 33% (95% PI: 30% to 36%) excess risk of experiencing prolonged symptoms in COVID-19 cases compared to controls in community-based studies with low risk of bias. Although studies that included controls showed, on the whole, lower net prevalence of Long Covid than studies that did not, the evidence from most of these studies is that COVID-19 is associated with a substantially higher risk of being ill 12 weeks after infection than those not infected.

In characterising Long Covid, the review demonstrated higher prevalence estimates in study samples where a substantial proportion of included individuals were hospitalised during the acute phase of the infection and/or had severe acute disease. It is difficult to comment on prevalence difference by ethnicity, deprivation or gender as although we conducted subgroup analyses by proportion of participants by gender or ethnicity in included studies, the difference between the prediction estimates may be related to other confounding factors, such as, for example, studies that included more males may indicate that they also include a high proportion of those who had severe acute illness(144). Many studies did not report ethnicity or deprivation. These factors will be important to include in future studies if a comprehensive understanding of Long Covid and inequity is to be gained.

Long Covid’s proposed pathophysiological mechanisms are multiple and potentially overlapping including persisting viral reservoirs, immune dysfunction, micro-clotting and end-organ damage(145). It is concerning that studies that specifically investigated for pathology tend to report higher prevalence estimates than those depending on healthcare records or even self reporting of symptoms. The review found that Long Covid presents a significant burden of functional disability, symptoms and pathology, with a pooled estimate of 34.5% of people not returning to full health/fitness after at least 12 weeks, and estimates of the most common symptoms/pathology including lung pathology (38.9%), fatigue (34.5%), breathing problems (14.9%), sleep problems (13.2%) and tingling or itching (11.3%). The paucity of long-term longitudinal studies following individuals’ disease progression means it is difficult to comment on which symptoms are most persistent over time.

The UK’s Office for National Statistics (ONS) produces population-level Long Covid prevalence estimates where the denominator is the whole population in the specific reported population group, for example, by age, sex, or occupation(146). These fall out of our inclusion criteria. The ONS also produced prevalence estimates based on following up those with confirmed SARSCoV2 infection and we used the most recent estimate within the review’s search period(9). This study used multiple approaches including assessing individual symptoms compared to controls and asking participants if they believe they have Long Covid. The latter approach, in the absence of a standardised method of assessment, may realistically be the best way to assess the presence of Long Covid as most people will take the combination of their symptoms, duration, fluctuation, effect on functional ability and change from pre-COVID19 health to shape their responses.

The lack of consensus on the precise definition of Long Covid plays an important part in the wide differences in prevalence assessments, however we found that specifically the way the question is asked and the source of retrieved clinical information at follow-up are likely to play a crucial role. The ONS study is an example of how different methods of assessment at time of follow-up can produce substantially different Long Covid estimates(9). This was illustrated by our analysis where studies that asked about multiple symptoms/domains tended to report higher prevalence estimates than single domain studies. Our analysis indicated higher prevalence estimates with longer follow-up time, though we recognise these were mostly not within-study comparisons. However, in four of ten longitudinal studies, prevalence was higher at the time of the second follow-up. These results could be explained by several factors e.g. by the episodic nature of Long Covid, whereby in the early stages people may feel they have got over their illness, but with passing time and phases of relapse and remittance, people may be more cautious about reporting they have recovered. People may also be developing new symptoms over time, or perhaps there is more study drop-out by people who feel they have recovered. Overall however, the results indicate that, over time, prevalence does not substantially reduce.

Studies that used questionnaires/surveys to ask participants about their symptoms, health status or quality of life tend to report higher prevalence estimates than those that recorded symptoms from healthcare records’ clinical coding. This is manifested in the prevalence from Al-Aly et al(16) studies being on the lower side in our analysis as we only included those with symptoms rather than recorded post-COVID-19 pathology, and such symptoms are expected to be severe enough to prompt seeking medical help and being recorded in medical notes. Studies that had dedicated pathology follow-up and discovery of COVID-19 patients tended to report the highest prevalence. This is possibly because, in addition to pathology that leads to recognisable signs and symptoms, specific medical investigations as part of the research protocol can pick up latent pathology that may not be accompanied by clinical manifestations.

Studies such as Al-Aly et al investigating medical diagnoses in the period following COVID-19, report cardiovascular, neurological, and other system-specific clinical sequelae providing a substantial excess burden in those who survived the acute phase of COVID-19(13). However, there is no agreement yet whether these outcomes are classed as Long Covid. They are generally not recorded by symptom studies and the WHO does not yet specifically include such outcomes within its clinical case definition of Post-COVID-19 Condition (also known as Long Covid) (1). A specific pathology diagnosed after COVID-19 could have been triggered by the infection, but identification as such will depend on the extent of clinical investigations identifying and labelling specific pathology as opposed to differences in the disease manifestation themselves.

Other sources of heterogeneity between studies include study design with some including assessment at one point in time, whereas others were longitudinal where assessment of COVID-19 status was conducted prior to the development of Long Covid. This assessment itself varied in terms of using PCR or antigen testing or self-reporting of history of acute infection.

Ideally, excess absolute risk in comparison to controls is a good measure to estimate the burden of Long Covid. This is likely dependent on the approach to control selection, whether based on self-report of absence of infection history or lab results that are not accurate enough to ascertain the state of previous infection (antigen or antibody), and timing of assessment given the predominant episodic nature of Long Covid.

Few studies had a low risk of bias, which suggests there is a gap in the evidence base for strong studies of Long Covid prevalence. In terms of causal inference, many studies were liable to potential collider bias, which presented as selection bias caused by restricting analyses to people who were hospitalised, self-selected for PCR or lateral flow tests based on symptoms, or simply volunteered their study participation(147). Similarly, our exploration of potential sources of heterogeneity may be prone to table 2 fallacy in the original studies, where these subgroups do not derive from the focal research question, so should be interpreted descriptively rather than causally(148).

The strengths of our review include comprehensive electronic searching for relevant studies and comprehensive assessment of risk of bias, data extraction and checking with each of these processes being done independently by two authors. We also adapted the Newcastle-Ottawa scale (Supplementary Table 3) for this prevalence systematic review which can be used by other researchers for risk assessment and/or to build high quality study designs. The quality assessment criteria and process were discussed within the study team which includes two authors with lived experience of Long Covid.

Our review was limited by the substantial between study heterogeneity. We used the most common reported symptom estimate for studies and did not combine multiple individual symptoms into one overall estimate of prevalence of Long Covid. The symptom with the highest prevalence differed from study to study, so may not be entirely comparable. We did not include more recent studies that assessed the prevalence of Long Covid following infection with different variants of SARSCoV2 and/or in double or triple vaccinated populations. Recent estimates point to a prevalence of 4-5% of reporting Long Covid at 12 to 16 weeks after first confirmed SARSCoV2 infection depending on variant, with no evidence of difference between variants among those who are triple vaccinated when infected(149). In those double vaccinated, the prevalence of persistent symptoms was around 10% compared to 15% of unvaccinated controls(150).

We extracted estimates of “new-onset” Long Covid/symptoms where possible. Where the proportion is of a symptom like fatigue for example, we picked the one quoted as new-onset fatigue if available, or we downgraded quality because it was not possible to ascertain that the symptom is ‘new’ following infection. Because Long Covid is a novel condition, prevalence of the condition is considered equivalent to cumulative incidence. When comparing with controls, we estimated cumulative incidence from reported absolute risk, when appropriate. When reporting risk ratio, we included incidence rate ratio and hazard ratios, but did not consider the odds ratio an adequate approximation because of the high potential prevalence in some populations.

We know that significant numbers of people experience ill health following SARSCoV2 infection. Long Covid impacts on society, particularly in places with continuing waves of infection. Through reviewing how different research approaches attempted to quantify the population burden of Long Covid, our findings provide insight into how to get more accurate estimates of prevalence and severity. With quantification of prevalence and the associated inequity, we can understand the investment needed for prevention, diagnosis, and treatment as well as the policy decisions needed to resource healthcare and social care services both adequately and equitably, and to mitigate the wider social and economic impact of Long Covid.

# Contributors

NAA, DCG, RT, AA, VL, MW conceptualised and designed the study. MW drafted the protocol and search strategy with input from all co-authors. VL conducted the search. All authors contributed to screening the articles. MW, DCG, NZ, RT, CC extracted and quality-assessed the data. NAA, MW, DCG, NZ, CC contributed to the process of checking and verifying the extracted data. DCG planned and conducted the statistical analyses and produced the forest plots. MW, DCG, NZ, NAA interpreted the data and drafted the manuscript. All authors reviewed the final manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

# Potential conflicts of interest

The authors declare no competing interests.

# Data sharing

All data used in this review is available in the published included studies. Data extractions and analytic code is available from the authors on reasonable request.

# Acknowledgements

We thank Hannah Davies for her input in conceptualising this review. MW was supported by an NIHR Pre-doctoral Local Authority Fellowship (Ref: 302098). RT and VL are supported by the Research, Evidence and Development Initiative (READ-It: project number 300342-104) which is funded by UK aid from the UK government. NZ is supported by NIHR Applied Research Collaboration Wessex. DCG is a co-investigator on the NIHR-funded LOCOMOTION study. NAA has lived experience of Long Covid, is a co-investigator on the NIHR-funded STIMULATE-ICP and HI-COVE studies, has contributed in an advisory capacity to WHO and the EU Commission’s Expert Panel on effective ways of investing in health meetings in relation to post-COVID-19 condition, and has acted as a collaborator on some of the UK’s Office for National Statistics outputs on the prevalence of Long Covid. AA has lived experience of Long Covid, is a co-founder of the Patient-Led Research Collaborative and has contributed in an advisory capacity to NIH, CDC and WHO. The views and opinions expressed in this review are those of the authors and do not necessarily reflect those of the NIHR, the Department of Health and Social Care or the UK government’s official policies.

For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

# References

1. World Health Organisation. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Internet; 2021 2021.

2. National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19. Internet; 2022. Contract No.: 1.14.

3. Centers for Disease Control and Prevention (CDC). Post-COVID Conditions: Overview for Healthcare Providers. Internet; 2021 9 July 2021.

4. Nehme M, Braillard O, Alcoba G, Aebischer Perone S, Courvoisier D, Chappuis F, et al. COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings. Annals of Internal Medicine. 2020;174(5):723-5.

5. Ziauddeen N, Gurdasani D, O’Hara ME, Hastie C, Roderick P, Yao G, et al. Characteristics and impact of Long Covid: Findings from an online survey. PLOS ONE. 2022;17(3):e0264331.

6. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine. 2021;38.

7. Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services. BMC Health Services Research. 2020;20(1):1144.

8. Kingstone T, Taylor AK, Donnell CA, Atherton H, Blane DN, Chew-Graham CA. Finding the 'right' GP: a qualitative study of the experiences of people with long-COVID. BJGP Open. 2020;4(5):bjgpopen20X101143.

9. Office for National Statistics. Technical article: Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. In: Statistics OfN, editor. Office for National Statistics2021.

10. WHO COVID-19 Research Database [Internet]. 2022. Available from: <https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/>.

11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

12. StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC; 2021.

13. Migliavaca CB, Stein C, Colpani V, Barker TH, Ziegelmann PK, Munn Z, et al. Meta-analysis of prevalence: I2 statistic and how to deal with heterogeneity. Research Synthesis Methods. 2022;13(3):363-7.

14. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society). 2009;172(1):137-59.

15. Abdelrahman MM, Abd-Elrahman NM, Bakheet TM. Persistence of symptoms after improvement of acute COVID19 infection, a longitudinal study. Journal of medical virology. 2021;93(10):5942-6.

16. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259-64.

17. Blomberg B, Mohn KG-I, Brokstad KA, Zhou F, Linchausen DW, Hansen B-A, et al. Long COVID in a prospective cohort of home-isolated patients. Nature medicine. 2021;27(9):1607-13.

18. Aminian A, Bena J, Pantalone KM, Burguera B. Association of obesity with postacute sequelae of COVID-19. Diabetes, Obesity & Metabolism. 2021;23(9):2183-8.

19. David TA, Fergus WH, Alice M, Anna M, Jason V, Marie A, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up; results from a prospective UK cohort.

20. Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. The Lancet Regional Health Europe. 2021;6:100122.

21. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ (Clinical research ed). 2021;372:n693.

22. Baricich A, Borg MB, Cuneo D, Cadario E, Azzolina D, Balbo PE, et al. Midterm functional sequelae and implications in rehabilitation after COVID-19: a cross-sectional study. European journal of physical and rehabilitation medicine. 2021;57(2):199-207.

23. Becker JH, Lin JJ, Doernberg M, Stone K, Navis A, Festa JR, et al. Assessment of Cognitive Function in Patients After COVID-19 Infection. JAMA network open. 2021;4(10):e2130645.

24. Bellan M, Soddu D, Balbo PE, Baricich A, Zeppegno P, Avanzi GC, et al. Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. JAMA network open. 2021;4(1):e2036142.

25. Blanco JR, Cobos-Ceballos MJ, Navarro F, Sanjoaquin I, Arnaiz de Las Revillas F, Bernal E, et al. Pulmonary long-term consequences of COVID-19 infections after hospital discharge. Clinical Microbiology & Infection. 2021;27(6):892-6.

26. Bliddal S, Banasik K, Pedersen OB, Nissen J, Cantwell L, Schwinn M, et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Scientific Reports. 2021;11(1):13153.

27. Boscolo-Rizzo P, Guida F, Polesel J, Marcuzzo AV, Capriotti V, D'Alessandro A, et al. Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19). International Forum of Allergy and Rhinology. 2021.

28. Carrillo-Garcia P, Garmendia-Prieto B, Cristofori G, Montoya IL, Hidalgo JJ, Feijoo MQ, et al. Health status in survivors older than 70 years after hospitalization with COVID-19: observational follow-up study at 3 months. European geriatric medicine. 2021;12(5):1091-4.

29. Caruso D, Guido G, Zerunian M, Polidori T, Lucertini E, Pucciarelli F, et al. Post-Acute Sequelae of COVID-19 Pneumonia: Six-month Chest CT Follow-up. Radiology. 2021;301(2):E396-E405.

30. Caspersen IH, Magnus P, Trogstad L. Excess risk and clusters of symptoms after COVID-19 in a large Norwegian cohort. European Journal of Epidemiology. 2022;37(5):539-48.

31. Castro VM, Rosand J, Giacino JT, McCoy TH, Perlis RH. Case-control study of neuropsychiatric symptoms in electronic health records following COVID-19 hospitalization in 2 academic health systems. Molecular Psychiatry. 2022.

32. Chai C, Feng X, Lu M, Li S, Chen K, Wang H, et al. One-year mortality and consequences of COVID-19 in cancer patients: A cohort study. IUBMB life. 2021;73(10):1244-56.

33. Cirulli ET, Schiabor Barrett KM, Riffle S, Bolze A, Neveux I, Dabe S, et al. Long-term COVID-19 symptoms in a large unselected population. medRxiv. 2020:2020.10.07.20208702.

34. Clavario P, De Marzo V, Lotti R, Barbara C, Porcile A, Russo C, et al. Cardiopulmonary exercise testing in COVID-19 patients at 3 months follow-up. International journal of cardiology. 2021;340:113-8.

35. Cristillo V, Pilotto A, Cotti Piccinelli S, Zoppi N, Bonzi G, Gipponi S, et al. Age and subtle cognitive impairment are associated with long-term olfactory dysfunction after COVID-19 infection. Journal of the American Geriatrics Society. 2021;69(10):2778-80.

36. Diaz-Fuentes G, Roa-Gomez G, Reyes O, Singhal R, Venkatram S. Coronavirus Pneumonia: Outcomes and Characteristics of Patients in an Inner-City Area after 3 Months of Infection. Journal of clinical medicine. 2021;10(15).

37. Domenech-Montoliu S, Puig-Barbera J, Pac-Sa MR, Vidal-Utrillas P, Latorre-Poveda M, Rio-Gonzalez AD, et al. ABO Blood Groups and the Incidence of Complications in COVID-19 Patients: A Population-Based Prospective Cohort Study. International journal of environmental research and public health. 2021;18(19).

38. Erol N, Alpinar A, Erol C, Sari E, Alkan K. Intriguing New Faces Of Covid-19: persisting Clinical Symptoms And Cardiac Effects in Children. Cardiology in the young. 2021:1-27.

39. Evans RA, Leavy OC, Richardson M, Elneima O, McAuley HJC, Shikotra A, et al. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. The Lancet Respiratory Medicine. 2022;10(8):761-75.

40. Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. The Lancet Respiratory Medicine. 2021;9(11):1275-87.

41. Fernandez-de-Las-Penas C, Gomez-Mayordomo V, de-la-Llave-Rincon AI, Palacios-Cena M, Rodriguez-Jimenez J, Florencio LL, et al. Anxiety, depression and poor sleep quality as long-term post-COVID sequelae in previously hospitalized patients: A multicenter study. The Journal of infection. 2021;83(4):496-522.

42. Fernandez-de-Las-Penas C, Guijarro C, Plaza-Canteli S, Hernandez-Barrera V, Torres-Macho J. Prevalence of Post-COVID-19 Cough One Year After SARS-CoV-2 Infection: A Multicenter Study. Lung. 2021;199(3):249-53.

43. Fernandez-de-Las-Penas C, Palacios-Cena D, Gomez-Mayordomo V, Rodriuez-Jimenez J, Palacios-Cena M, Velasco-Arribas M, et al. Long-term post-COVID symptoms and associated risk factors in previously hospitalized patients: A multicenter study. Journal of Infection. 2021;83(2):237-79.

44. Frija-Masson J, Debray MP, Boussouar S, Khalil A, Bancal C, Motiejunaite J, et al. Residual ground glass opacities three months after Covid-19 pneumonia correlate to alteration of respiratory function: The post Covid M3 study. Respiratory Medicine. 2021;184:106435.

45. Froidure A, Mahsouli A, Liistro G, De Greef J, Belkhir L, Gerard L, et al. Integrative respiratory follow-up of severe COVID-19 reveals common functional and lung imaging sequelae. Respiratory medicine. 2021;181:106383.

46. Fu L, Fang Y, Luo D, Wang B, Xiao X, Hu Y, et al. Pre-hospital, in-hospital and post-hospital factors associated with sleep quality among COVID-19 survivors 6 months after hospital discharge: cross-sectional survey in five cities in China. BJPsych open. 2021;7(6):e191.

47. Gaber TAK, Ashish A, Unsworth A. Persistent post-covid symptoms in healthcare workers. Occupational Medicine (Oxford). 2021;71(3):144-6.

48. Garcia-Abellan J, Padilla S, Fernandez-Gonzalez M, Garcia JA, Agullo V, Andreo M, et al. Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study. Journal of clinical immunology. 2021;41(7):1490-501.

49. Garratt AM, Ghanima W, Einvik G, Stavem K. Quality of life after COVID-19 without hospitalisation: Good overall, but reduced in some dimensions. The Journal of infection. 2021;82(5):186-230.

50. Gonzalez-Hermosillo JA, Martinez-Lopez JP, Carrillo-Lampon SA, Ruiz-Ojeda D, Herrera-Ramirez S, Amezcua-Guerra LM, et al. Post-Acute COVID-19 Symptoms, a Potential Link with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A 6-Month Survey in a Mexican Cohort. Brain sciences. 2021;11(6).

51. Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, et al. Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia. Radiology. 2021;299(1):E177-E86.

52. Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. JAMA. 2021;325(19):2015-6.

53. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet (London, England). 2021;397(10270):220-32.

54. Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet (London, England). 2021;398(10302):747-58.

55. Jacobson KB, Rao M, Bonilla H, Subramanian A, Hack I, Madrigal M, et al. Patients With Uncomplicated Coronavirus Disease 2019 (COVID-19) Have Long-Term Persistent Symptoms and Functional Impairment Similar to Patients with Severe COVID-19: A Cautionary Tale During a Global Pandemic. Clinical Infectious Diseases. 2021;73(3):e826-e9.

56. Kashif A, Chaudhry M, Fayyaz T, Abdullah M, Malik A, Anwer JMA, et al. Follow-up of COVID-19 recovered patients with mild disease. Scientific Reports. 2021;11(1):13414.

57. Kim Y, Kim S-W, Chang H-H, Kwon KT, Bae S, Hwang S. Significance and Associated Factors of Long-Term Sequelae in Patients after Acute COVID-19 Infection in Korea. Infection & chemotherapy. 2021;53(3):463-76.

58. Lemhofer C, Sturm C, Loudovici-Krug D, Best N, Gutenbrunner C. The impact of Post-COVID-Syndrome on functioning - results from a community survey in patients after mild and moderate SARS-CoV-2-infections in Germany. Journal of Occupational Medicine & Toxicology. 2021;16(1):45.

59. Li X, Shen C, Wang L, Majumder S, Zhang D, Deen MJ, et al. Pulmonary fibrosis and its related factors in discharged patients with new corona virus pneumonia: a cohort study. Respiratory Research. 2021;22(1):203.

60. Liao T, Meng D, Xiong L, Wu S, Yang L, Wang S, et al. Long-Term Effects of COVID-19 on Health Care Workers 1-Year Post-Discharge in Wuhan. Infectious Diseases and Therapy. 2021.

61. Liao X, Wang Y, He Z, Yun Y, Hu M, Ma Z, et al. Three-Month Pulmonary Function and Radiological Outcomes in COVID-19 Survivors: A Longitudinal Patient Cohort Study. Open forum infectious diseases. 2021;8(9):ofaa540.

62. Liu Y-H, Wang Y-R, Wang Q-H, Chen Y, Chen X, Li Y, et al. Post-infection cognitive impairments in a cohort of elderly patients with COVID-19. Molecular neurodegeneration. 2021;16(1):48.

63. Liyanage-Don NA, Cornelius T, Sanchez JE, Trainor A, Moise N, Wainberg M, et al. Psychological Distress, Persistent Physical Symptoms, and Perceived Recovery After COVID-19 Illness. Journal of General Internal Medicine. 2021;36(8):2525-7.

64. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA network open. 2021;4(2):e210830.

65. Lucidi D, Molinari G, Silvestri M, De Corso E, Guaraldi G, Mussini C, et al. Patient-reported olfactory recovery after SARS-CoV-2 infection: A 6-month follow-up study. International Forum of Allergy & Rhinology. 2021;11(8):1249-52.

66. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Pang P, et al. Long COVID in Patients With Mild to Moderate Disease: Do Thyroid Function and Autoimmunity Play a Role? Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2021;27(9):894-902.

67. Maestre-Muniz MM, Arias A, Mata-Vazquez E, Martin-Toledano M, Lopez-Larramona G, Ruiz-Chicote AM, et al. Long-Term Outcomes of Patients with Coronavirus Disease 2019 at One Year after Hospital Discharge. Journal of clinical medicine. 2021;10(13).

68. Martinez AE, Banderet F, Labhardt ND, Battegay M. Long-term outcome after SARS-CoV-2 infection in healthcare workers: a single centre cohort study. Swiss medical weekly. 2021;151:w30094.

69. Matteudi T, Luciani L, Fabre A, Minodier P, Boucekine M, Bosdure E, et al. Clinical characteristics of paediatric COVID-19 patients followed for up to 13 months. Acta paediatrica. 2021.

70. Mazza MG, Palladini M, De Lorenzo R, Magnaghi C, Poletti S, Furlan R, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. Brain, behavior, and immunity. 2021;94:138-47.

71. Mechi A, Al-Khalidi A, R ALD, Al-Dujaili MN, Al-Buthabhak K, Alareedh M, et al. Long-term persistent symptoms of COVID-19 infection in patients with diabetes mellitus. International Journal of Diabetes in Developing Countries. 2021.

72. Mei Q, Wang F, Bryant A, Wei L, Yuan X, Li J. Mental health problems among COVID-19 survivors in Wuhan, China. World psychiatry : official journal of the World Psychiatric Association (WPA). 2021;20(1):139-40.

73. Mei Q, Wang F, Yang Y, Hu G, Guo S, Zhang Q, et al. Health Issues and Immunological Assessment Related to Wuhan's COVID-19 Survivors: A Multicenter Follow-Up Study. Frontiers in medicine. 2021;8:617689.

74. Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. PLoS ONE [Electronic Resource]. 2021;16(7):e0254523.

75. Milanese M, Anselmo M, Buscaglia S, Garra L, Goretti R, Parodi L, et al. COVID-19 6 months after hospital discharge: pulmonary function impairment and its heterogeneity. ERJ open research. 2021;7(3).

76. Millet C, Narvaneni S, Chaudhry S, Shamoon Y, Chaudhry A, Farokhian A, et al. The Long Haul: a follow up study of patients diagnosed with COVID-19 one year ago at an urban medical center in New Jersey. Chest. 2021;160(4):A566-A7.

77. Mohiuddin Chowdhury ATM, Karim MR, Ali MA, Islam J, Li Y, He S. Clinical Characteristics and the Long-Term Post-recovery Manifestations of the COVID-19 Patients-A Prospective Multicenter Cross-Sectional Study. Frontiers in Medicine. 2021;8:663670.

78. Munblit D, Bobkova P, Spiridonova E, Shikhaleva A, Gamirova A, Blyuss O, et al. Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2021;51(9):1107-20.

79. Nabahati M, Ebrahimpour S, Khaleghnejad Tabari R, Mehraeen R. Post-COVID-19 pulmonary fibrosis and its predictive factors: a prospective study. Egyptian Journal of Radiology and Nuclear Medicine. 2021;52(1) (no pagination)(248).

80. Nehme M, Braillard O, Chappuis F, Courvoisier DS, Guessous I, CoviCare Study T. Prevalence of Symptoms More Than Seven Months After Diagnosis of Symptomatic COVID-19 in an Outpatient Setting. Annals of internal medicine. 2021;174(9):1252-60.

81. Nguyen N, Hoang VT, Lagier JC, Raoult D, Gautret P. Long-term persistence of olfactory and gustatory disorders in COVID-19 patients. Clinical microbiology and infection. 2021.

82. Nunez-Fernandez M, Ramos-Hernandez C, Garcia-Rio F, Torres-Duran M, Nodar-Germinas A, Tilve-Gomez A, et al. Alterations in Respiratory Function Test Three Months after Hospitalisation for COVID-19 Pneumonia: Value of Determining Nitric Oxide Diffusion. Journal of Clinical Medicine. 2021;10(10):14.

83. O'Keefe JB, Minton HC, Morrow M, Johnson C, Moore MA, O'Keefe GAD, et al. Postacute Sequelae of SARS-CoV-2 Infection and Impact on Quality of Life 1-6 Months After Illness and Association With Initial Symptom Severity. Open forum infectious diseases. 2021;8(8):ofab352.

84. Ong SWX, Fong S-W, Young BE, Chan Y-H, Lee B, Amrun SN, et al. Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. Open forum infectious diseases. 2021;8(6):ofab156.

85. Orru G, Bertelloni D, Diolaiuti F, Mucci F, Di Giuseppe M, Biella M, et al. Long-COVID Syndrome? A Study on the Persistence of Neurological, Psychological and Physiological Symptoms. Healthcare (Basel, Switzerland). 2021;9(5).

86. Osmanov I, Spiridonova E, Bobkova P, Gamirova A, Shikhaleva A, Andreeva M, et al. Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. The european respiratory journal. 2021.

87. Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2021;27(10):1507-13.

88. Peluso MJ, Kelly JD, Lu S, Goldberg SA, Davidson MC, Mathur S, et al. Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19. medRxiv : the preprint server for health sciences. 2021.

89. Petersen M, Kristiansen MF, Hanusson KD, Danielsen MEA, Steig B, Gaini S, et al. Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients. Clinical infectious diseases. 2020.

90. Qin W, Chen S, Zhang Y, Dong F, Zhang Z, Hu B, et al. Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up. European Respiratory Journal. 2021;58(1):07.

91. Qu G, Zhen Q, Wang W, Fan S, Wu Q, Zhang C, et al. Health-related quality of life of COVID-19 patients after discharge: A multicenter follow-up study. Journal of Clinical Nursing. 2021;30(11-12):1742-50.

92. Radtke T, Ulyte A, Puhan MA, Kriemler S. Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents. JAMA. 2021.

93. Rass V, Beer R, Schiefecker AJ, Kofler M, Lindner A, Mahlknecht P, et al. Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study. European journal of neurology. 2021;28(10):3348-59.

94. Riestra-Ayora J, Yanes-Diaz J, Esteban-Sanchez J, Vaduva C, Molina-Quiros C, Larran-Jimenez A, et al. Long-term follow-up of olfactory and gustatory dysfunction in COVID-19: 6 months case-control study of health workers. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2021;278(12):4831-7.

95. Righi E, Mirandola M, Mazzaferri F, Razzaboni E, Zaffagnini A, Erbogasto A, et al. Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19. Infectious diseases and therapy. 2021;10(3):1579-90.

96. Roessler M, Tesch F, Batram M, Jacob J, Loser F, Weidinger O, et al. Post COVID-19 in children, adolescents, and adults: results of a matched cohort study including more than 150,000 individuals with COVID-19. medRxiv. 2021:2021.10.21.21265133.

97. Romero-Duarte A, Rivera-Izquierdo M, Guerrero-Fernandez de Alba I, Perez-Contreras M, Fernandez-Martinez NF, Ruiz-Montero R, et al. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study. BMC medicine. 2021;19(1):129.

98. P S, Madhavan S, Pandurangan V. Prevalence, Pattern and Functional Outcome of Post COVID-19 Syndrome in Older Adults. Cureus. 2021;13(8):e17189.

99. Seeßle J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. Clinical Infectious Diseases. 2022;74(7):1191-8.

100. Shang YF, Liu T, Yu JN, Xu XR, Zahid KR, Wei YC, et al. Half-year follow-up of patients recovering from severe COVID-19: Analysis of symptoms and their risk factors. Journal of Internal Medicine. 2021;290(2):444-50.

101. Sibila O, Albacar N, Perea L, Faner R, Torralba Y, Hernandez-Gonzalez F, et al. Lung Function sequelae in COVID-19 Patients 3 Months After Hospital Discharge. Archivos de bronconeumologia. 2021;57:59-61.

102. Sigfrid L, Drake TM, Pauley E, Jesudason EC, Olliaro P, Lim WS, et al. Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. The Lancet Regional Health Europe. 2021;8:100186.

103. Simani L, Ramezani M, Darazam IA, Sagharichi M, Aalipour MA, Ghorbani F, et al. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. Journal of neurovirology. 2021.

104. Skala M, Svoboda M, Kopecky M, Kocova E, Hyrsl M, Homolac M, et al. Heterogeneity of post-COVID impairment: interim analysis of a prospective study from Czechia. Virology journal. 2021;18(1):73.

105. Skjorten I, Ankerstjerne OAW, Trebinjac D, Bronstad E, Rasch-Halvorsen O, Einvik G, et al. Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation. European Respiratory Journal. 2021;58(2):08.

106. Sonnweber T, Sahanic S, Pizzini A, Luger A, Schwabl C, Sonnweber B, et al. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. The European respiratory journal. 2021;57(4).

107. Soraas A, Bo R, Kalleberg KT, Stoer NC, Ellingjord-Dale M, Landro NI. Self-reported Memory Problems 8 Months After COVID-19 Infection. JAMA Network Open. 2021;4(7):e2118717.

108. Soraas A, Kalleberg KT, Dahl JA, Soraas CL, Myklebust TA, Axelsen E, et al. Persisting symptoms three to eight months after non-hospitalized COVID-19, a prospective cohort study. PloS one. 2021;16(8):e0256142.

109. Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax. 2020.

110. Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Prevalence and Determinants of Fatigue after COVID-19 in Non-Hospitalized Subjects: A Population-Based Study. International journal of environmental research and public health. 2021;18(4).

111. Stephenson T, Shafran R, De Stavola B, Rojas N, Aiano F, Amin-Chowdhury Z, et al. Long COVID and the mental and physical health of children and young people: national matched cohort study protocol (the CLoCk study). BMJ open. 2021;11(8):e052838.

112. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nature medicine. 2021;27(4):626-31.

113. Sykes D, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19 Symptom Burden: what is Long-COVID and How Should We Manage It? Lung. 2021.

114. Taboada M, Carinena A, Moreno E, Rodriguez N, Dominguez MJ, Casal A, et al. Post-COVID-19 functional status six-months after hospitalization. The Journal of infection. 2021;82(4):e31-e3.

115. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS medicine. 2021;18(9):e1003773.

116. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The lancet Psychiatry. 2021;8(5):416-27.

117. Tarsitani L, Vassalini P, Koukopoulos A, Borrazzo C, Alessi F, Di Nicolantonio C, et al. Post-traumatic Stress Disorder Among COVID-19 Survivors at 3-Month Follow-up After Hospital Discharge. Journal of general internal medicine. 2021;36(6):1702-7.

118. Tawfik HM, Shaaban HM, Tawfik AM. Post-covid-19 syndrome in egyptian healthcare staff: Highlighting the carers sufferings. Electronic Journal of General Medicine. 2021;18(3) (no pagination)(em291).

119. Taylor R, Trivedi B, Patel N, Singh R, Ricketts WM, Elliott K, et al. Post-COVID symptoms reported at asynchronous virtual review and stratified follow-up after COVID-19 pneumonia. Clinical medicine (London, England). 2021.

120. Tempany M, Leonard A, Prior AR, Boran G, Reilly P, Murray C, et al. The potential impact of post-COVID symptoms in the healthcare sector. Occupational medicine (Oxford, England). 2021;71(6-7):284-9.

121. Writing Committee for the CSG, Morin L, Savale L, Pham T, Colle R, Figueiredo S, et al. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA. 2021;325(15):1525-34.

122. Tholin B, Ghanima W, Einvik G, Aarli B, Bronstad E, Skjonsberg OH, et al. Incidence of thrombotic complications in hospitalised and non-hospitalised patients after COVID-19 diagnosis. British Journal of Haematology. 2021;194(3):542-6.

123. Tleyjeh IM, Saddik B, AlSwaidan N, AlAnazi A, Ramakrishnan RK, Alhazmi D, et al. Prevalence and predictors of Post-Acute COVID-19 Syndrome (PACS) after hospital discharge: A cohort study with 4 months median follow-up. PLOS ONE. 2021;16(12):e0260568.

124. Todt BC, Szlejf C, Duim E, Linhares AOM, Kogiso D, Varela G, et al. Clinical outcomes and quality of life of COVID-19 survivors: A follow-up of 3 months post hospital discharge. Respiratory Medicine. 2021;184:106453.

125. Tohamy D, Sharaf M, Abdelazeem K, Saleh MGA, Rateb MF, Soliman W, et al. Ocular Manifestations of Post-Acute COVID-19 Syndrome, Upper Egypt Early Report. Journal of multidisciplinary healthcare. 2021;14:1935-44.

126. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PloS one. 2020;15(11):e0240784.

127. Trunfio M, Venuti F, Alladio F, Longo BM, Burdino E, Cerutti F, et al. Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. Viruses. 2021;13(2).

128. Ursini F, Ciaffi J, Mancarella L, Lisi L, Brusi V, Cavallari C, et al. Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey. RMD Open. 2021;7(3):08.

129. Venturelli S, Benatti SV, Casati M, Binda F, Zuglian G, Imeri G, et al. Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation. Epidemiology and infection. 2021;149:e32.

130. Walle-Hansen MM, Ranhoff AH, Mellingsaeter M, Wang-Hansen MS, Myrstad M. Health-related quality of life, functional decline, and long-term mortality in older patients following hospitalisation due to COVID-19. BMC geriatrics. 2021;21(1):199.

131. Weng J, Li Y, Li J, Shen L, Zhu L, Liang Y, et al. Gastrointestinal sequelae 90 days after discharge for COVID-19. The lancet Gastroenterology & hepatology. 2021;6(5):344-6.

132. Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nature Communications. 2022;13(1):1957.

133. Xiong L, Li Q, Cao X, Xiong H, Huang M, Yang F, et al. Dynamic changes of functional fitness, antibodies to SARS-CoV-2 and immunological indicators within 1 year after discharge in Chinese health care workers with severe COVID-19: a cohort study. BMC Medicine. 2021;19(1):163.

134. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2021;27(1):89-95.

135. Yan B, Song L, Guo J, Wang Y, Peng L, Li D. Association Between Clinical Characteristics and Short-Term Outcomes in Adult Male COVID-19 Patients With Mild Clinical Symptoms: A Single-Center Observational Study. Frontiers in medicine. 2020;7:571396.

136. Yan X, Huang H, Wang C, Jin Z, Zhang Z, He J, et al. Follow-up study of pulmonary function among COVID-19 survivors 1 year after recovery. The Journal of infection. 2021;83(3):381-412.

137. Yin X, Xi X, Min X, Feng Z, Li B, Cai W, et al. Long-term chest CT follow-up in COVID-19 Survivors: 102-361 days after onset. Annals of Translational Medicine. 2021;9(15):1231.

138. Zayet S, Zahra H, Royer P-Y, Tipirdamaz C, Mercier J, Gendrin V, et al. Post-COVID-19 Syndrome: Nine Months after SARS-CoV-2 Infection in a Cohort of 354 Patients: Data from the First Wave of COVID-19 in Nord Franche-Comte Hospital, France. Microorganisms. 2021;9(8).

139. Zhan Y, Zhu Y, Wang S, Jia S, Gao Y, Lu Y, et al. SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection. Signal Transduction and Targeted Therapy. 2021;6(1) (no pagination)(368).

140. Zhang D, Zhang C, Li X, Zhao J, An C, Peng C, et al. Thin-section computed tomography findings and longitudinal variations of the residual pulmonary sequelae after discharge in patients with COVID-19: a short-term follow-up study. European Radiology. 2021;31(9):7172-83.

141. Zhang J, Xu J, Zhou S, Wang C, Wang X, Zhang W, et al. The characteristics of 527 discharged COVID-19 patients undergoing long-term follow-up in China. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021;104:685-92.

142. Zhang X, Wang F, Shen Y, Zhang X, Cen Y, Wang B, et al. Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China. JAMA network open. 2021;4(9):e2127403.

143. Zhou M, Xu J, Liao T, Yin Z, Yang F, Wang K, et al. Comparison of Residual Pulmonary Abnormalities 3 Months After Discharge in Patients Who Recovered From COVID-19 of Different Severity. Frontiers in medicine. 2021;8:682087.

144. Scully EP, Schumock G, Fu M, Massaccesi G, Muschelli J, Betz J, et al. Sex and Gender Differences in Testing, Hospital Admission, Clinical Presentation, and Drivers of Severe Outcomes From COVID-19. Open Forum Infectious Diseases. 2021;8(9):ofab448.

145. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023.

146. Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 September 2022. In: Statistics OfN, editor. 2022.

147. Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nature Communications. 2020;11(1):5749.

148. Westreich D, Greenland S. The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier Coefficients. American Journal of Epidemiology. 2013;177(4):292-8.

149. Office for National Statistics. Self-reported long COVID after infection with the Omicron variant in the UK: 18 July 2022. In: Statistics OfN, editor. 2022.

150. Ayoubkhani D, Bosworth ML, King S, Pouwels KB, Glickman M, Nafilyan V, et al. Risk of Long Covid in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study. Open Forum Infectious Diseases. 2022.

151. Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021;76:399-401.

|  | Author | Country | Study design (as described by study, \* if not stated) | Denominator[[1]](#footnote-2) | Controls  N, type | Setting | Age (years)  Mean/SD  Median (IQR) | % female | COVID-19 diagnostic method | Severity | Follow-up time[[2]](#footnote-3)  Days | Finding:  % with at least one symptom or pathology remaining at follow-up |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Abdelrahman, M et al(15) | Egypt | Prospective cohort | 172 | - | Hospitalised patients and non-hospitalised | 41.8/17.6 | 65.7 | ‘Tested positive' | 12.8% hospitalised (including 4% ICU) | 240-300 (range) following ‘improvement of acute COVID-19’ | 61.0% |
|  | Al-Aly, Z et al(16) | USA | Cohort with controls | 60255 | 4526737  without COVID-19 and not hospitalised | Non-hospitalised | 61 (4872) | 12.1 | ‘Positive test’ | - | 126b | 2.9% |
| 2a. | Al-Aly, Z et al (16) | USA | Cohort with controls | 11800 | 11868 hospitalised with seasonal influenza | Hospitalised patients | 70 (61-76) | 5.8 | PCR confirmed | 26.3% ICU | 150b | 9.2% |
|  | Aminian, A et al (18) | USA | Retrospective | 2839 | - | Hospitalised patients | 52.7/20.1 | 52.3 | PCR confirmed | ICU excluded | 243b | 44.2% |
|  | Arnold, D et al(151) | UK | Prospective cohort | 110 | - | Hospitalised patients | 60 (46-73) | 44.0 | PCR confirmed or clinico-radiological | Mixed | 90b | 73.6% |
|  | Augustin, M et al(20) | Germany | Longitudinal prospective cohort | 442 | - | Non-hospitalised patients | 43 (31-54) | 52.3 | PCR confirmed | 97.5% mild | 131b | 27.8% |
|  | Ayoubkhani, D et al(21) | UK | Observational retrospective matched cohort (with controls) | 47780 | 47780 matched for age, sex | Hospitalised patients | 64.5/19.2 | 45.1 | Laboratory confirmed or clinical diagnosis | 9.9% ICU | 140e | 21.5 |
|  | Baricich, A et al(22) | Italy | Cross-sectional | 204 | - | Hospitalised patients | 57.9/12.8 | 40.0 | ‘Confirmed diagnosis’ | 13% ICU | 124.7e | 32.4% |
|  | Becker, J et al(23) | USA | Cross-sectional | 740 | - | Hospitalised patients, outpatients and ER attendees | 49 (38-59) | 63.0 | Tested positive or antibody positive | - | 228a | 24.1% |
|  | Bellan, M et al(24) | Italy | Prospective cohort | 238 | - | Hospitalised patients | 61 (50-71) | 40.3 | PCR confirmed bronchial swab, serological testing, or suggestive CT | 27.7% did not require oxygen  11.8% ICU | 91-121e | 53.8% |
|  | Blanco, J et al(25) | Spain | Prospective | 100 | - | Hospitalised patients | 54.9/10.3 | 36.0 | PCR confirmed | 47% severe | 104b | 52.0% |
|  | Bliddal, S et al(26) | Denmark | Cohort | 129 | - | Non-hospitalised patients | 44.8 (13.6) | 70.0 | PCR confirmed | Non-hospitalised | 90a | 40.3% |
|  | Blomberg, B et al(17) | Norway | Prospective cohort with controls | 312 | 60 seronegative household contacts | Hospitalised patients and non-hospitalised | 46 (30-58) | 51.0 | ‘Tested positive’ | 2% asymptomatic,78% symptomatic in community, 21% hospitalised | 152-213 (range) after illness | 60.6% |
|  | Boscolo-Rizzo, P et al(27) | Italy | Prospective | 304 | - | Community | 47 (n/a) | 60.9 | PCR confirmed | Mild-to-moderate (home-isolated) | 365a | 53.0% |
|  | Carrillo-Garcia, P et al(28) | Spain | Longitudinal observational | 165 | - | Hospitalised older adult patients | 88.5/6.7 | 69.1 | PCR confirmed and suspected cases (clinical, imaging and laboratory results) | - | 3m post-hospital discharge | 66.2% |
|  | Caruso, D et al(29) | Italy | Prospective | 118 | - | Hospitalised patients with interstitial pneumonia | 65/12 | 53.0 | PCR confirmed | Moderate to severe | 6m post-hospital admission | 77.1% |
|  | Caspersen, I et al(30) | Norway | Matched cohort | 774 | 72953 | Community (MoBa: population-based pregnancy cohort study) | 25+ | 58.0 | PCR confirmed | - | 334-365 (range) after infection | 16.5% |
|  | Castro, V et al(31) | USA | Retrospective cohort | 5571 | 30193 hospitalised COVID-19 negative patients | Hospitalised patients | 63 (50-76) | 47.0 | PCR confirmed | 13% ICU | 91-150 days post-hospital admission | 10.9% |
|  | Chai, C et al(32) | China | Multi-centre ambidirectional cohort | 546 | -\*\*\* | Hospitalised cancer and non-cancer patients | 65 (59-70) | 51.0 | PCR confirmed | 24% severe | 370d | 28.6% |
|  | Cirulli, E et al(33) | USA | Prospective longitudinal | 357 | - | Community | - | - | PCR confirmed | - | 90a | 14.8% | |
|  | Clavario, P et al(34) | Italy | Prospective cohort | 200 | - | Hospitalised patients | 58.8 (51.6-66.0) | 43.0 | PCR confirmed | 89% required at least oxygen support | 107f | 80.0% |
|  | Cristillo, V et al(35) | Italy | Cohort\* | 101 | - | Hospitalised patients | 63.6/12.9 | 27.7 | ‘Hospitalised for COVID-19’ | hospitalized for mild to moderate COVID | 6m post-hospital discharge | 49.5% |
|  | Diaz-Fuentes, G et al(36) | USA | Retrospective cohort | 111 | - | Hospitalised patients and non-hospitalised | 60/13.9 | 53.1 | Positive nasal swab | Mixed | 12 weeks post-infection | 79.3% |
|  | Domenech-Montoliu, S et al(37) | Spain | Prospective cohort | 483 | - | Community | 37.2/17.1 | 62.1 | Laboratory confirmed | 11.2% asymptomatic | 7m post-infection | 53.4% |
|  | Erol, N et al(38) | Turkey | Cohort | 121 | 95 randomly selected from non-COVID patients attending the ward | Hospitalised and non-hospitalised children | 9.2 (10.9-17.9) | 46.2 | ‘Tested positive’ | 22.3% hospitalised | 5.6m post-infection | 37.2% |
|  | Evans R, et al (PHOSP-COVID study) (39) **(¥)** | UK | Prospective longitudinal cohort | 804 | - | Hospitalised patients | 58.0/12.6 | 39.0 | PCR confirmed or clinician diagnosed | Mixed | 365f | 48.8% |
|  | Evans, R et al (PHOSP-COVID study)(40) **(¥)** | UK | Prospective longitudinal cohort | 1077 | - | Hospitalised patients | 57.9/13 | 35.7 | Confirmed or clinician-diagnosed | Mixed | 176f | 92.6% |
|  | Fernandez-de-Las-Penas, C et al(43) **(∞)** | Spain | Multi-centre observational | 1142 | - | Hospitalised patients | 61/17 | 47.5 | PCR confirmed | 7% ICU | 210e | 81.4% |
|  | Fernandez-de-Las-Penas, C et al(41) **(∞)** | Spain | Multicentre observational | 1142 | - | Hospitalised patients | 61/17 | 47.4 | PCR confirmed | 7% ICU | 210e | 49.6% |
|  | Fernandez-de-Las-Penas, C et al(42) **(∞)** | Spain | Multi-centre cohort | 1950 | - | Hospitalised patients | 61/16 | 46.9 | PCR confirmed | 6.6% ICU | 340e | 81.2% |
|  | Frija-Masson, J et al(44) | France | Retrospective | 137 | - | Not stated | 59 (50-68) | 49.0 | PCR confirmed | 90.5% required respiratory support | 3m post-symptom onset | 75.2% |
|  | Froidure, A et al(45) | Belgium | Single-centre cohort | 107 | - | Hospitalised patients | 60 (53-68) | 41.0 | PCR confirmed | Severe and critical | 103b | 68.2% |
|  | Fu, L et al(46) | China | Cross-sectional | 199 | - | Hospitalised patients | 18+ | 53.3 | Not stated | 2.5% ICU | 6m post-hospital discharge | 10.1% |
|  | Gaber, T et al(47) | UK | Cross-sectional | 138 | - | 98% non-hospitalised health care workers | - | 92.0 | 83% PCR confirmed  17% no laboratory confirmation | 2% hospitalised | 4m post-infection | 44.2% |
|  | Garcia-Abellan, J et al(48) | Spain | Prospective longitudinal | 116 | - | Hospitalised patients | 64 (54-76) | 39.7 | PCR confirmed | 14% ICU | 180a | 24.1% |
|  | Garratt, A et al(49) **(▪)** | Norway | Cross-sectional survey of a geographical cohort | 447 | Norwegian general population norms | Community | 49.5/15.3 | 56.0 | PCR confirmed | Non-hospitalised | 117.5b | 35.3% |
|  | Gonzalez-Hermosillo, J et al(50) | Mexico | Prospective longitudinal | 130 | - | Hospitalised patients | 51/14 | 34.6 | PCR confirmed | Moderate to severe | 3m post-hospital discharge | 91.5% |
|  | Han, X et al(51) | China | Prospective longitudinal | 114 | - | Hospitalised patients | 54/12 | 30.0 | PCR confirmed | Severe | 175a | 62.3% |
|  | Havervall, S et al(52) | Sweden | Cohort with controls | 323 | 1072 seronegative | Health care workers | 43 (33-52) | 83.0 | Seropositive | mild/moderate (severe excluded) | 122a | 21.4% |
|  | Huang, C et al(53) **(Ω)** | China | Ambidirectional cohort | 1655 | - | Hospitalised patients | 57 (47-65) | 48.0 | Laboratory confirmed | 68% required oxygen therapy  4% ICU | 186b | 76.4% |
|  | Huang, L et al(54) **(Ω)** | China | Ambidirectional cohort with controls | 1227 | 3383 community dwelling without SARS-CoV-2 infection, 1164 matched pairs | Hospitalised patients | 59 (49-67) | 47.0 | Laboratory confirmed | 4% ICU | 185b | 68.0% |
|  | Jacobson, K et al(55) | USA | Cohort\* | 118 | - | Hospitalised patients and non-hospitalised | 43.3/14.4 | 46.6 | PCR confirmed | 18.6% hospitalised 9.3% ICU | 119.3b | 66.9% |
|  | Kashif, A et al(56) | Pakistan | Cohort\* | 242 | - | Hospitalised patients and non-hospitalised | 18-65 | 30.6 | PCR confirmed | Mild | 3m post-hospital discharge or visit | 41.7% |
|  | Kim, Y et al(57) | S Korea | Cohort\* | 900 | - | Hospitalised patients and non-hospitalised | 31 (24-47) | 69.7 | PCR confirmed | 12% moderate or severe | 195b | 65.7% |
|  | Lemhofer, C et al(58) | Germany | Cross-sectional | 365 | - | Community | 49.8/16.9 | 59.2 | ‘Positively tested’ | Mild and moderate | 93.7% - more than 3months post-infection | 61.9% |
|  | Li, X et al(59) | China | Cohort | 289 | - | Hospitalised patients | 43.6/17.4 | 48.8 | PCR confirmed | 19.4% severe/critical | 90-150 (range) post- symptom onset | 59.9% |
|  | Liao, T et al(60) | China | Cohort\* | 303 | - | Hospitalised healthcare workers | 39 (33-48) | 80.5 | ‘Infected with COVID-19’ | 62.7% critical/severe | 395f | 37.3% |
|  | Liao, X et al(61) | China | Longitudinal cohort | 142 | - | Hospitalised patients | 47.5 (36-57) | 48.8 | PCR confirmed | 21.1% severe | 90f | 85.9% |
|  | Liu, Y-H et al(62) | China | Cross-sectional | 1301 | 466 uninfected spouses who lived together | Hospitalised patients, elderly | 68 (66-74) | 53.3 | ‘Diagnosis of COVID-19’ | 1.8% ICU | 6m post-hospital discharge | 28.7% |
|  | Liyanage-Don, A et al(63) | USA | Cohort\* | 153 | - | Hospitalised patients | 54.5/16.7 | 39.9 | ‘Hospitalised for COVID-19’ | 5.9% ICU | 111b | 64.7% |
|  | Logue, J et al(64) | USA | Longitudinal prospective cohort (cross sectional for controls\*) | 177 | 21, ‘healthy controls recruited via email and flyer advertisements’ | Hospitalised and outpatients | 48 / 15.2 | 57.1 | laboratory-confirmed | 6.2% asymptomatic, 84.7% mild illness, 9.0% moderate or severe disease | 169b | 30.0% |
|  | Lucidi, T et al(65) | Italy | Observational retrospective | 110 | - | Not stated | 41.4/12.3 | 63.6 | ‘COVID-19 positive patients’ | - | 6.1 +/- 1.1 months post-infection | 36.4% |
|  | Lui, D et al(66) | China (HK) | Prospective | 204 | - | Hospitalised patients | 55 (44-63) | 53.4 | PCR confirmed | 3.9% severe | 89d | 20.1% |
|  | Maestre-Muniz, M et al(67) | Spain | Cross-sectional | 543 | - | Hospitalised patients and ER attendees | 65.1/17.5 | 49.3 | Laboratory confirmed | Mixed | 12m post-hospital discharge | 56.9% |
|  | Martinez, A et al(68) | Switzerland | Retrospective cohort | 260 | - | Healthcare workers | Mean range 30-39 | 75.4 | ‘Positive test' | 1.2% hospitalised | 168b | 26.5% |
|  | Matteudi, T et al(69) | France | Prospective cohort | 137 | - | Hospitalised patients and outpatients, paediatric | 9.3 (n/a) | - | PCR confirmed | 27% asymptomatic | 180a | 16.8% |
|  | Mazza, M et al(70) | Italy | Prospective cohort | 226 | - | Hospitalised patients and ER attendees | 58.5/12.8 | 34.1 | PCR confirmed | 78% hospitalised | 90.1e | 35.8% |
|  | Mechi, A et al(71) | Iraq | Single-centre cross-sectional | 112 | - | Hospitalised patients and non-hospitalised | 50.6/13.4 | 34.0 | Laboratory confirmed | 46.4% hospitalised | 9m after acute infection | 82.1% |
|  | Mei, Q et al(72) **(†)** | China | Cohort\* | 4328 | 1500, random sample of general population | Hospitalised patients | 59 (47-68) | 54.1 | Met relevant clinical criteria | Not defined | 144f | 14.2% |
|  | Mei, Q et al(73) **(†)** | China | Prospective cohort | 3677 | - | Hospitalised patients | 59 (47-68) | 55.5 | PCR confirmed | 33.7% severe, 2.6% critical | 144f | 26.5% |
|  | Menges, D et al(74) | Switzerland | Population-based prospective cohort | 431 | - | Community | 47 (33-58) | 49.7 | PCR confirmed | 10.7% asymptomatic, 38.1% severe/very severe | 220b | 24.6% |
|  | Milanese, M et al(75) | Italy | Prospective cohort | 135 | - | Hospitalised patients | 59/11 | 33.0 | Not stated | Moderate and severe | 182e | 47.4% |
|  | Millet, C et al(76) | USA | Prospective cohort | 173 | - | Hospitalised patients and outpatients | 51.5/n/a | 50.6 | PCR confirmed | - | 12m post-diagnosis | 48.0% |
|  | Mohiuddin Chowdhury, A et al(77) | Bangladesh | Prospective multi-centre cross-sectional | 313 | - | Hospitalised patients and outpatients | 37.7/13.7 | 19.8 | PCR confirmed | Not critically ill (ICU/HDU) | 140g | 21.4% |
|  | Munblit, D et al(78) | Russia | Longitudinal cohort | 2649 | - | Hospitalised patients | 56 (46-66) | 51.1 | PCR confirmed and clinically diagnosed | 2.6% severe | 218f | 57.9% |
|  | Nabahati, M et al(79) | Iran | Prospective cross-sectional | 173 | - | Hospitalised patients | 53.6/13.7 | 67.1 | PCR confirmed | 54% severe | 90e | 52.0% |
|  | Nehme, M, et al(80) | Switzerland | Prospective cohort | 410 | - | Outpatients | 42.7/12.9 | 67.1 | PCR confirmed | Mild and moderate | 7-9m post-diagnosis | 39.0% |
|  | Nguyen, N et al(81) | France | Cohort\* | 125 | - | Hospitalised | 36 (27-48)) | 55.0 | PCR confirmed | Non-severe | 210a | 24.0% |
|  | Nunez-Fernandez, M et al(82) | Spain | Prospective cohort | 200 | - | Hospitalised patients | 62 (n/a) | 40.5 | PCR confirmed | 15.5% ICU | 84e | 29.0% |
|  | O’Keefe, J et al(83) | USA | Cross-sectional | 198 | - | Outpatients | 45/14 | 74.2 | PCR confirmed | 29.7% moderate, 1.1% severe | 119b | 39.9% |
|  | Office for National Statistics(9) | UK | Prospective cohort w | 21374 | - | Community | 2+ | 52.3 | PCR confirmed | - | 12 weeks post-infection | 11.7% |
|  | Ong, S et al(84) | Singapore | Prospective longitudinal multi-centre cohort | 175 | - | Hospitalised patients | 44 (33-56) | 24.6 | PCR confirmed | 30.1% severe | 90e | 7.4% |
|  | Orru, G et al(85) | Italy | retrospective | 152 | - | Community via social media | - | - | Self-report | - | At least 3m post-infection | 74.3% |
|  | Osmanov, I et al(86) | Russia | Prospective cohort | 518 | - | Hospitalised children | 10.4 (3.0-15.2) | 52.1 | PCR confirmed | 2.7% severe (NIV/IV or PICU) | 256f | 24.3% |
|  | Peghin M, et al(87) | Italy | Bidirectional prospective cohort | 599 | - | Hospitalised patients and outpatients | 53/15.8 | 53.4 | NAAT for confirmed cases; laboratory, imaging or serology for suspected cases | Mixed | 191b | 40.2% |
|  | Peluso, M et al(88) | USA | Cohort | 143 | - | Hospitalised patients and non-hospitalised | 48 (37-57) | 44.0 | RNA-confirmed | Mixed | 4m post-test or first symptoms | 62.2% |
|  | Petersen, M et al(89) | Faroe Islands | Longitudinal | 180 | - | 96% non-hospitalised patients | 39.9/19.4 | 54.4 | PCR confirmed | 4.4% asymptomatic | 125a | 52.8% |
|  | Qin, W et al(90) | China | Prospective cohort | 647 | - | Hospitalised patients | 58/15 | 56.0 | PCR confirmed | 38% severe | 3m post-hospital discharge | 13.4% |
|  | Qu, G et al(91) | China | Multicentre follow-up | 540 | - | Hospitalised patients | 47.5 (37-57) | 50.0 | PCR confirmed | 9.4% severe | 3m post-hospital discharge | 32.6% |
|  | Radtke, T et al(92) | Switzerland | Longitudinal cohort | 109 | 1246 seronegative | Community, children and adolescents | 6-16 | 53.0 | Antibody positive | No hospitalisation | 84a | 3.7% |
|  | Rass, V et al(93) | Austria | Prospective observational cohort | 135 | - | Hospitalised and outpatients | 56 (48-68) | 39.0 | PCR confirmed | 23% severe (ICU), 53% moderate (hospitalised) | 90a | 60.7% |
|  | Riestra-Ayora, J et al(94) | Spain | Prospective case–control | 195 | 125 healthcare workers with negative PCR | Hospitalised and non-hospitalised healthcare workers | 41.6/n/a | 80.0 | PCR confirmed | 4.4% hospitalised | 6m post-positive test | 26.7% |
|  | Righi, E et al(95) | Italy | Prospective cohort | 421 | - | Hospitalised patients and outpatients | 56 (45-66) | 45.1 | PCR confirmed | 52% hospitalised, 20% ICU | 84a | 19.7% |
|  | Roessler, M et al(96)  *Split cohort (Adults)* | Germany | Matched cohort | 145184 | - | Community | - | 60.2 | ‘Laboratory confirmed’ | 5.8% hospitalised, 2.1% intensive care or ventilation | >90a | 9.2% |
| 83a. | Roessler, M et al(96)  *Split cohort (Children)* | Germany | Matched cohort | 11950 | - | Community, children | - | 48.1 | Laboratory confirmed | 1% hospitalised, 0.4% ICU | >90a | 6.1% |
|  | Romero-Duarte, A et al(97) | Spain | Retrospective longitudinal observational follow-up | 797 | - | Hospitalised patients | 63/14.4 | 46.3 | PCR confirmed | 10.8% ICU | 6m post-hospital discharge | 63.9% |
|  | Sathyamurthy, P et al(98) | India | Single-centre prospective cohort | 279 | - | Hospitalised older adult patients | 71.0/5.6 | 36.2 | PCR confirmed | 41.6% severe to critical | 90e | 23.7% |
|  | Seeβle, J et al(99) | Germany | Prospective cohort | 146 | - | Hospitalised and outpatients | 57 (50-63) | 57.0 | PCR confirmed | 15.6% mild, 55.2% moderate, 25.0% severe, 4.2% critical | 140-154 (range) following symptom onset | 73.3% |
|  | Shang, Y et al(100) | China | Cohort | 796 | - | Hospitalised patients | 62 (51-69) | 49.2 | PCR confirmed | 90.8% severe, 9.2% critical | 6m post-hospital discharge | 55.4% |
|  | Sibila, O et al(101) | Spain | Prospective cohort | 172 | - | Hospitalised patients | 56.1/19.8 | 43.0 | Not stated | moderate and severe  43% ICU | 101.5e | 57.0% |
|  | Sigfrid, L et al(102) | UK | Prospective cohort | 327 | - | Hospitalised patients | 59.7 (51.7-67.7) | 41.3 | PCR confirmed or ‘clinically diagnosed highly suspected’ | 20.8% no O2, 36.1% supplemental O2, 15.0% non-invasive O2, 28.1% mechanical ventilation | 222b | 93.3% |
|  | Simani, L et al(103) | Iran | Cohort\* | 120 | - | Hospitalised patients | 54.6/16.9 | 33.3 | Spiral chest CT scan or PCR confirmed | 7.5% ICU | 183e | 10.0% |
|  | Skala, M et al(104) | Czech Republic | Prospective cohort | 102 | - | Hospitalised patients and outpatients | 46.7/ n/a | 53.9 | PCR confirmed | 14.7% hospitalised | 3m after testing positive | 54.9% |
|  | Skjorten, I et al(105) | Norway | Multi-centre prospective cohort | 126 | - | Hospitalised patients | 56.2/12.7 | 38.5 | ‘Discharge diagnosis of COVID-19’ | 20% ICU | 104f | 46.8% |
|  | Sonnweber, T et al(106) | Austria | Prospective observational | 145 | - | Hospitalised and outpatients | 57/14 | 43.0 | PCR confirmed | 22% ICU | 103a | 54.9% |
|  | Soraas, A et al(107) **(π)** | Norway | Cohort | 651 | 5712 SARS-CoV-2–negative + 3342 randomly selected untested | Community | 48.6/13.6 | 57 | PCR confirmed | Non-hospitalised, mild | 258a | 51.9% |
|  | Soraas, A et al(108) **(π)** | Norway | Prospective cohort | 672 | 6006 SARS-COV2-negative patients | Community | 48.5/13.5 | 56.8 | PCR confirmed | Non-hospitalised | 126a | 56.2% |
|  | Stavem, K et al(109) **(▪)** | Norway | Cross-sectional | 451 | - | Community survey | 49.7/15.2 | 56.0 | PCR confirmed | - | 117b | 41.0% |
|  | Stavem, K et al(110) **(▪)** | Norway | Cross-sectional mixed-mode | 458 | - | Community | 49.5/15.3 | 56.0 | PCR confirmed | - | 117.5b | 46.0% |
|  | Stephenson, T et al(111) | UK | Matched cohort | 3065 | 3739 who tested negative | Community, adolescents | 11-17 | 63.5 | PCR confirmed | 35.4% symptomatic | 104b | 66.5% |
|  | Sudre, C et al(112) | UK, USA and Sweden | Prospective observational cohort | 4182 | 4,182, matched PCR negative\*\*\* | Community | 46.0/15.8 | 57.0 | PCR confirmed | 13.9% visited hospital | 84a | 2.6% |
|  | Sykes, D et al(113) | UK | Cohort\* | 127 | - | Hospitalised patients | 59.6/14 | 34.3 | PCR confirmed | 87% required oxygen and/or respiratory support, 20% ICU | 113f | 59.1% |
|  | Taboada, M et al(114) | Spain | Cross-sectional observational | 183 | - | Hospitalised patients | 6.9/14.1 | 40.5 | PCR confirmed | 18.2% ICU | 6 months post- hospitalisation | 47.5% |
|  | Taquet, M et al(116) **(◊)** | Primarily USA | Retrospective cohort with matching | 236,379 | 105,579 diagnosed with flu, 236,038 with any other RTI including flu | healthcare organisations including hospitals, primary care, and specialist providers | 46/19.7 | 55.6 | "confirmed diagnosis" | Mixed | 180a | 12.8% |
|  | Taquet,. M et al(115) **(◊)** | USA | Retrospective cohort | 273618 | 106,578 matched cohort with influenza and without a diagnosis of COVID-19 or positive test | Hospitalised patients and non-hospitalised | 46.3/19.8 | 55.6 | ‘Confirmed diagnosis’, ICD-10 code | Mixed | 90a | 36.5% |
|  | Tarsitani, L et al(117) | Italy | Cohort follow-up | 115 | - | Hospitalised patients | 57 (48-66) | 46.0 | ‘Confirmed COVID-19’ | 23% ICU | 3m post-hospital discharge | 29.6% |
|  | Tawfik, H et al(118) | Egypt | Retrospective cohort | 120 | - | Hospitalised and non-hospitalised healthcare workers | 33.7/7.29 | 58.0 | PCR confirmed | 28.3% moderate, 10.0% severe | At least 3m post-positive test | 33.3% |
|  | Taylor, R et al(119) | UK | Cohort\* | 545 | - | Hospitalised patients | 58.6/15.3 | 38.2 | ‘Presumed and confirmed’ | - | 16weeks post-hospital discharge | 47.9% |
|  | Tempany, M et al(120) | Republic of Ireland | Cross-sectional\* | 217 | - | Healthcare workers | 20-69 | 80.0 | PCR confirmed or antibody positive | - | At least 12 weeks post- +ve test | 53.5% |
|  | The Writing Committee for the COMEBAC Study Group(121) | France | Prospective uncontrolled cohort | 478 | - | Hospitalised patients | 60.9/16.1 | 42.1 | PCR confirmed or by CT scan | 29.7% ICU, remainder hospitalised | 113f | 51.0% |
|  | Tholin, B et al(122) **(▪)** | Norway | Multicentre prospective cohort | 683 | - | Hospitalised patients and non-hospitalised | 52.9/15.5 | 51.0 | PCR confirmed, or discharge diagnosis of ‘confirmed or unconfirmed COVID-19’ | Mixed | 3m after discharge (hospitalised), 4m post-symptom onset (non-hospitalised) | 1.8% |
|  | Tleyjeh, I et al(123) | Saudi Arabia | Prospective cohort | 222 | - | Hospitalised patients | 52.5/14.0 | 23.0 | PCR confirmed | Mixed  30.2% ICU | 122f | 56.3% |
|  | Todt, B et al(124) | Brazil | Single-centre cohort | 239 | - | Hospitalised patients | 53.6/14.9 | 40.2 | PCR confirmed | 69.7% severe | 3m post-hospital discharge | 40.2% |
|  | Tohamy, D et al(125) | Egypt | Retrospective comparative study with controls | 100 | 100 randomly recruited from hospital registration system without COVID-19 | Hospitalised and outpatients | 55.5/6.2 | 43.0 | PCR confirmed | 25% moderate, 45% severe | 3m post-hospital discharge | 5.0% |
|  | Townsend, L et al(126) | Republic of Ireland | Cross-sectional\* | 128 | - | Hospitalised and non-hospitalised | 49.5/15 | 53.9 | PCR confirmed | 55.5% hospitalised | 72f | 57.8% |
|  | Trunfio, M et al(127) | Italy | Cross-sectional | 168 | - | Hospitalised patients and outpatients | 56 (43-69) | 42.0 | PCR confirmed | 63.7% hospitalised | 194b | 24.4% |
|  | Ursini, F et al(128) | Italy | Cross-sectional | 616 | - | Community via social media | 45/12 | 77.4 | Positive nasopharyngeal swab | 10.7% hospitalised, 1.6% ICU | 6 ± 3m post-positive test | 43.8% |
|  | Venturelli, S et al(129) | Italy | Cohort\* | 767 | - | Emergency Department and hospitalised patients | 63/13.6 | 32.9 | PCR confirmed | 88.4% admitted  8.6% ICU | 105b | 51.4% |
|  | Walle-Hansen, M et al(130) | Norway | Cohort | 106 | - | Hospitalised older adult patients | 74.3/n/a | 43.0 | PCR confirmed | 26% severe | 186f | 53.8% |
|  | Weng, J et al(131) | China | Retrospective | 117 | - | Hospitalised patients | - | 44.4 | PCR confirmed | 28.2% severely ill | 89.5e | 44.4% |
|  | Whitaker, M et al(132) | UK | Random community-based survey (REACT-2) | 76,155 | - | Community | -18+ | 57.3 | Self-reported | 0.8% admitted to hospital | 84a | 37.7% |
|  | Xiong, L et al(133) | China | Ambidirectional cohort | 162 | - | Hospitalised healthcare workers | 36 (31-43) | 77.0 | ‘Infected with COVID-19’ | 100% severe, 5% ICU | 153f | 70.4% |
|  | Xiong, Q et al(134) | China | Longitudinal with controls | 538 | 184, volunteers | Hospitalised patients | 52 (41-62) | 54.5 | “confirmed” | 5% critical, 33.5% severe | 97f | 49.6% |
|  | Yan, B et al(135) | China | Prospective observational | 125 | - | Mobile cabin hospital, adult males | 35 (30-49) | 0.0 | ‘Diagnosed with COVID-19’ | asymptomatic / mild symptoms | 84e | 0.0% |
|  | Yan, X et al(136) | China | Cohort | 119 | - | Hospitalised patients | 53.0/12.2 | 59.0 | PCR confirmed | 24% severe | 365e | 39.5% |
|  | Yin, X et al(137) | China | Retrospective analysis | 337 | - | Hospitalised patients | 53.5/14.8 | 49.5 | PCR confirmed | 12.8% severe, 3.6% ICU | 203a | 55.8% |
|  | Zayet, S et al(138) | France | Retrospective cohort | 354 | - | Hospitalised patients and outpatients | 49.6/18.7 | 63.0 | PCR confirmed | 34.2% hospitalised, 5% ICU | 289a | 35.9% |
|  | Zhan, Y et al(139) | China | Prospective cohort | 121 | - | Hospitalised patients | 49 (40-57) | 58.7 | PCR confirmed | 15.7% severe | 348b | 29.8% |
|  | Zhang, D et al(140) | China | Retrospective comparative | 122 | - | Hospitalised patients | 51 (31.8-61.0) | 50.3 | PCR confirmed | mild cases excluded, only patients with pulmonary sequelae at discharge included | 92f | 54.9% |
|  | Zhang, J et al(141) | China | Cohort\* | 245 | - | Hospitalised patients | 43 (33-54) | 43.8 | Nucleic acid testing | 9.3% severe/critical | 90e | 72.7% |
|  | Zhang, X et al(142) | China | Retrospective multi-centre cohort | 2433 | - | Hospitalised patients | 60 (49-68) | 50.5 | Laboratory confirmed | 27.9% severe | 364f | 45.0% |
|  | Zhou, M et al(143) | China | Prospective cohort with controls | 164 | 42 healthy controls – negative nucleic acid and antibody tests | Hospitalised patients | - | 56.9 | PCR and antibody test | 54.6% severe | 129b (severe cases)  125b (mild) | 69.5% |

# Figure legends

Figure 1: Study selection

Figure 2: Forest plot of prevalence of Long Covid in the included studies, with 95% prediction intervals

Figure 3: Forest plot of prevalence of Long Covid in the included studies by method of outcome assessment, with 95% prediction intervals

Figure 4: Forest plot of risk of Long Covid in included studies with community-based samples and controls assessed as having low risk of bias, with 95% prediction intervals

Figure 5: Forest plot of individual symptoms, pathology and functional disability identified in the included studies, with 95% prediction intervals

# Supplementary material

Supplementary appendix

1. Different denominators specific to each outcome have been used in cases where data are incomplete or where individual symptoms have different denominators. [↑](#footnote-ref-2)
2. a – mean no. of days post-symptom onset or positive test; b - median no. of days post-symptom onset or positive test; c – mean no. of days post-hospital admission; d - median no. of days post-hospital admission; e – mean no. of days post-hospital discharge; f – median no. of days post-hospital discharge; g – mean no. of days post-negative test following infection; h - median no. of days post-negative test following infection.

   Papers coded variously with the following symbols are different publications from the same study data: **Ω, ▪, ◊, ¥, †, ∞, π**  [↑](#footnote-ref-3)